drugset
drugset / Trial / NCT00015990

Thalidomide in Treating Patients With Myelodysplastic Syndrome

NCT00015990 ↗

Phase 2 Completed 29 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of thalidomide in treating patients who have myelodysplastic syndrome. Thalidomide may improve the immune system's ability to fight myelodysplastic syndrome

Timeline

Start
2001-04
Primary completion
2007-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified — Oral

Indications

chronic myelomonocytic leukemia myelodysplastic syndrome with excess blasts myelodysplastic syndrome with ring sideroblasts refractory anemia with excess blasts in transformation